A multicenter retrospective study analysing efficacy and safety of first-line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma
Latest Information Update: 13 May 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 13 May 2021 New trial record